Form 4: CareDx Director Hannah Valantine Executes Stock Transactions

Director Hannah Valantine acquired 9,795 restricted stock units and sold 12,103 shares of CareDx, Inc. common stock.

Summary

• Director Hannah Valantine acquired 9,795 restricted stock units (RSUs) on June 12, 2026.
• The director sold 12,103 shares of common stock on June 15, 2026, at a weighted average price of $23.1123 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.
• Following these transactions, the director holds 36,686 shares of CareDx, Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-established 10b5-1 plan, which is a routine administrative action.

Positives

• The director maintains a significant equity stake of 36,686 shares in the company.

Negatives

• The director reduced her total beneficial ownership through the sale of 12,103 shares.

Risks

• Future share price volatility may impact the value of the director's remaining holdings.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-planned 10b5-1 programs, are standard corporate governance practices and generally reflect personal financial management rather than a change in outlook on the company's operational health.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard industry practice for corporate insiders to avoid potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact expected as the transactions were pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

CareDx, CDNA, Insider Trading, Form 4, Biotech, Equity Ownership